內地民企研發投入500家榜單:華為、阿里及騰訊居三甲
據《中新網》報道,2021粵港澳大灣區民營企業科技創新峰會暨民營企業科技成果對接會上,全國工商聯發布了「2021民營企業研發投入500家」榜單,華為投資控股有限公司位居榜首,阿里巴巴(09988.HK)、騰訊控股(00700.HK)分別位列第二和第三位。而第四位是浙江吉利控股,第五位及第六分別是百度(09888.HK)及京東(09618.HK)。
據了解,內地「2021民營企業研發投入500家」榜單入圍門檻為上年度研發投入2.37億人民幣。500家企業研發費用總額7,429億元人民幣,其中,研發投入最高的企業研發費用1,419億人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.